Application Detail

Description of Medical Service

Susoctocog alfa is a treatment used to replace the missing protein needed for blood clotting (Factor VIII), which is less susceptible to being inhibited by autoantibodies than the patient’s own protein. This allows clotting to occur and assists to stop the bleeding. It also allows for the patient’s protein levels to be measured, to assist with guiding dosing and optimising treatment efficacy and safety.

Description of Medical Condition

Acquired Haemophilia A is a condition where patients present with spontaneous bleeding despite no history of a bleeding disorder. Patients have the required protein needed for blood clotting, but autoantibodies develop to inhibit this normal function.

Reason for Application

Referral from National Blood Authority

Medical Service Type

Therapeutic

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1169 KB)
Application Form (Word 201 KB)

Consultation Survey

Consultation Survey (PDF 660 KB)
Consultation Survey (Word 27 KB)
PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 10 February 2023 for it to be considered by MSAC at its March 2023 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Bypassing PASC

ESC

9-10 February 2023

MSAC

30-31 March 2023